Skip navigation

Examining the pharmacological role in the opioid epidemic with multi-stakeholder discussions on policy, reimbursement and regulatory approval

March 6-7, 2018
  • Washington, DC

The nation is in an opioid crisis. As a nation there are many ways we are addressing this epidemic. Abuse-Deterrent Formulations is an important part of that solution. Yet there are challenges to its efficacy, issues regarding reimbursement and questions about their role in addressing addiction. Attend this conference with executives from Pharmaceutical and Healthcare organizations as well as academic and government representatives.

What are the top benefits attendees will receive by attending?

  • Update on FDA Policy for ADFs
  • Discussions on how to address reimbursement challenges from payors
  • Guidelines on Class 4 labeling
  • Debate on efficacy of state legislation and enforcement of utilizing ADFs
  • Point/counter point panels with leading industry executives discussing efficacy and reimbursement

Previous Attendee Acclaim:

Excellent conference. Organizers did a great job of coming up with unique talks

VP Regulatory Affairs KemPharm

Great opportunity to network and learn about new label developments in the field of ADF from multiple stakeholders

Int. Tech. Project Leader, Grünenthal Great demo on manipulation!

Good content; not repetitive; keep including FDA

CCO, Alcobra

Abuse-Deterrent Formulations Summit

Examining the pharmacological role in the opioid epidemic with multi-stakeholder discussions on policy, reimbursement and regulatory approval

The nation is in an opioid crisis. As a nation there are many ways we are addressing this epidemic. Abuse-Deterrent Formulations is an important part of that solution. Yet there are challenges to its efficacy, issues regarding reimbursement and questions about their role in addressing addiction. Attend this conference with executives from Pharmaceutical and Healthcare organizations as well as academic and government representatives.

What are the top benefits attendees will receive by attending?

  • Update on FDA Policy for ADFs
  • Discussions on how to address reimbursement challenges from payors
  • Guidelines on Class 4 labeling
  • Debate on efficacy of state legislation and enforcement of utilizing ADFs
  • Point/counter point panels with leading industry executives discussing efficacy and reimbursement

Previous Attendee Acclaim:

Excellent conference. Organizers did a great job of coming up with unique talks

VP Regulatory Affairs KemPharm

Great opportunity to network and learn about new label developments in the field of ADF from multiple stakeholders

Int. Tech. Project Leader, Grünenthal Great demo on manipulation!

Good content; not repetitive; keep including FDA

CCO, Alcobra